Novartis | NOVN - Biaya Penjualan





Biaya Penjualan Perubahan Tanggal
AbbVie USD 4.29B 73M 2026-06
Alcon AG USD 1.18B 26M 2026-03
Almirall EUR 199.26M 7.76M 2026-06
Amgen USD 1.87B 271M 2026-06
AstraZeneca USD 2.52B 2.73B 2026-06
Autolus Therapeutics Ltd USD 24.57M 762K 2026-03
Bayer EUR 4.54B 692M 2026-06
Biogen USD 945.1M 147.6M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Fresenius EUR 4.4B 111M 2026-06
Fresenius Medical Care EUR 3.55B 117.58M 2026-06
Genmab DKK 84M 19M 2026-06
Gilead Sciences USD 1000M 445M 2026-06
GlaxoSmithKline GBP 2.07B 192M 2026-06
GRIFOLS EUR 1.17B 90M 2026-06
Hikma Pharmaceutical USD 959M 492.5M 2025-12
J&J USD 8B 67M 2026-06
Lakefront Biotherapeutics EUR 4.8M 4.34M 2026-03
Lonza CHF 2.28B 189M 2025-06
Merck EUR 2.07B 219M 2026-03
Merck USD 3.14B 200M 2026-06
Novartis USD 3.71B 251M 2026-06
Novartis USD 3.46B 83M 2026-03
Novo Nordisk DKK 17.1B 3.5B 2026-06
Orion EUR 181.7M 18M 2026-06
Pfizer USD 4.09B 498M 2026-06
Philips EUR 2.21B 70M 2026-06
Recordati EUR 199.38M 3.22M 2026-06
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Roche Holding CHF 7.85B 630M 2026-06
Sanofi EUR 3.02B 656M 2026-06
UCB EUR 1.07B 146M 2025-12